Aardvark Adventures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures

DAVE 209.97

+3.0%

Dec 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ~digs	11/27/2007 9:45:09 PM
	Read Replies (1) of 7944

[LEVP.OB] LEV PHARMACEUTICALS > 1.94 +0.03 ( +1.57%) Lev Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops and commercializes therapeutic products for the treatment of inflammatory diseases primarily in the United States. It develops C1-esterase inhibitor (C1-INH), a Phase III clinical trial product for the acute and prophylactic treatment of hereditary angioedema, which is a genetic disorder characterized by episodic attacks of edema in the extremities, face, abdomen, and airway passages. Lev Pharmaceuticals' product is also used for the treatment of acute myocardial infarction or heart attack, and other diseases and disorders.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next